GlassScriptPhysician profile
Sarah Bhatti
NPI 1922483791
$9,784.41
in general payments reported to CMS, 2019-2025
26 companies · $2,949 in 2025
The $2,949 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,709 · 2022: $1,040 · 2023: $1,270 · 2024: $2,815 · 2025: $2,949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,584 · Education: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,583.87 |
| Education | $450.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,752.07 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Abbvie INC. | $1,626.25 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $702.03 | 2021-2025 | Dupixent, Libtayo |
| Mayne Pharma Commercial LLC | $642.68 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $636.35 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $596.23 | 2021-2025 | |
| Janssen Biotech, INC. | $432.44 | 2023-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $364.86 | 2021-2025 | |
| Incyte Corporation | $364.77 | 2021-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $342.23 | 2023-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $306.41 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $272.04 | 2021-2025 | Siliq, Jublia, Cabtreo |
| Almirall LLC | $259.48 | 2021-2025 | Seysara, Klisyri |
| Lilly USA, LLC | $230.06 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $223.43 | 2023-2025 | Zoryve |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $195.86 | 2022-2024 | Otezla |
| Pfizer INC. | $190.55 | 2021-2025 | |
| Vyne Pharmaceuticals INC. | $188.42 | 2021 | |
| Ucb, INC. | $157.45 | 2021-2025 | Bimzelx |
| Organon LLC | $86.31 | 2025 | Vtama |
| Journey Medical Corporation | $70.31 | 2022-2025 | |
| Dermavant Sciences, INC. | $57.98 | 2023-2024 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $41.98 | 2022 | |
| Epi Health, LLC | $19.82 | 2022 | |
| Nabriva Therapeutics, Plc | $12.65 | 2021 | |
| Ani Pharmaceuticals, INC. | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Bhatti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.